Triplet Therapeutics
Jean-François Formela is a partner at Atlas Venture which he joined in 1993 to build the US life sciences franchise. He focuses on new advances in biology and drug discovery technologies as well as novel therapeutics.
He is chairman of IFM Therapeutics and serves on the boards of Intellia Therapeutics (NASDAQ: NTLA), F-star, Korro Therapeutics, Kyn Therapeutics, Spero Therapeutics (NASDAQ: SPRO), Translate Bio (NASDAQ: TBIO), which he co-founded, and Triplet Therapeutics, Inc.
Jean-François has been involved in the formation of many biotech companies such as Exelixis, Morphosys, Decode, Translate Bio, Intellia and IFM.
He received his M.D. from Paris University School of Medicine and his M.B.A. from Columbia University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Triplet Therapeutics
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.